Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Raw Materials (2021 - 2025)

Historic Raw Materials for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Raw Materials rose 283.15% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 283.15%. This contributed to the annual value of $3.0 million for FY2024, which is 106.74% up from last year.
  • Mirum Pharmaceuticals' Raw Materials amounted to $2.9 million in Q3 2025, which was up 283.15% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Raw Materials registered a high of $3.0 million during Q4 2024, and its lowest value of $444000.0 during Q3 2023.
  • Moreover, its 5-year median value for Raw Materials was $2.9 million (2025), whereas its average is $2.3 million.
  • Over the last 5 years, Mirum Pharmaceuticals' Raw Materials had its largest YoY gain of 52837.84% in 2024, and its largest YoY loss of 106.74% in 2024.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Raw Materials stood at $856000.0 in 2021, then rose by 0.23% to $858000.0 in 2022, then surged by 249.42% to $3.0 million in 2023, then rose by 1.07% to $3.0 million in 2024, then fell by 5.31% to $2.9 million in 2025.
  • Its Raw Materials was $2.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.0 million in Q1 2025.